The topic was stopped after scoping, this means the topic will not proceed to a Technology Appraisal
Status Topic selection
Technology type Medicine
Decision Not selected
Reason for decision Not eligible for Health Technology Evaluation guidance
ID number 3799

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
25 April 2024 Topic selection. Deselected by TSOP
04 May 2021 The topic liposomal bupivacaine for treating post-operative pain was scoped by the National Institute for Health and Care Excellence (NICE) as a Technology Appraisal Following the written consultation on the draft remit and scope and discussions at the scoping workshop, NICE compiled a summary of its findings into a report that was discussed at the Topic Selection Oversight Panel (TSOP) in April 2021. The report included advice and recommendations to aid the decision-making process as to whether the topic should continue to be appraised in the NICE work programme. TSOP concluded the topic liposomal bupivacaine for treating post-operative pain was not suitable for a Technology Appraisal since the benefits of this technology cannot be adequately quantified within the Technology Appraisal methods framework. The possibility of an evidence summary will be explored. If you have questions regarding this statement please contact the Scoping Project manager, Michelle Adhemar at
22 January 2021 (10:00) Scoping workshop
25 November 2020 - 23 December 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we select topics for development, please see our page about topic selection